The combined contraceptive vaginal ring (NuvaRing®) and lipid metabolism: A comparative study

Contraception

Volumn 69, Issue 5, 2004, Pages 389-394

  Tuppurainen, M ^a   Klimscheffskij, R ^b   Venhola, M ^c   Dieben, Th O M ^d  

^a Laboratorio Gyne Oy   (Finland)

^b YTHS   (Finland)

^c Myyrmaen Terveyskaeskus   (Finland)

^d Clinical Development Department   (Netherlands)

Author keywords

Estrogen; Etonogestrel; Lipid metabolism; NuvaRing; Oral contraceptives; Progestogen

Indexed keywords

APOLIPOPROTEIN B; CORTICOSTEROID; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS ETONOGESTREL; ETONOGESTREL; HIGH DENSITY LIPOPROTEIN; LEVONORGESTREL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; SEX HORMONE BINDING GLOBULIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTRACEPTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LIPID METABOLISM;

ADMINISTRATION, INTRAVAGINAL; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; APOLIPOPROTEINS; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CONTRACEPTIVE AGENTS, FEMALE; CONTRACEPTIVE DEVICES, FEMALE; CONTRACEPTIVES, ORAL, COMBINED; DESOGESTREL; ETHINYL ESTRADIOL; FEMALE; HUMANS; LEVONORGESTREL; LIPIDS; TRIGLYCERIDES;

EID: 1942423255     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2004.01.004     Document Type: Article

References (19)

1. Roumen F.J.M.E., Apter D., Mulders T.M.T., Dieben T.O.M. Efficacy, tolerability and acceptability of NuvaRing, a novel contraceptive vaginal ring. Hum Reprod. 16:2001;469-475.
2. Timmer C.J., Mulders T.M.T. Pharmacokinetics of NuvaRing, a combined contraceptive vaginal ring. Clin Pharmacokinet. 39:2000;233-242.
3. Bjarnadóttir R.I., Tuppurainen M., Killick S.R. Comparison of cycle control and tolerability with a combined contraceptive vaginal ring and oral levonorgestrel/ethinylestradiol. Am J Obstet Gynecol. 186:2002;389-395.
4. Dieben T.O.M., Roumen F.J.M.E., Apter D. Efficacy, cycle control and user acceptability of a novel combined contraceptive vaginal ring. Obstet Gynecol. 100:2002;585-593.
5. Mulders T.M.T., Dieben T.O.M. Ovulation inhibition of the novel combined contraceptive vaginal ring NuvaRing® Fertil Steril. 75:2001;865-870.
6. Mulders T.M.T., Dieben T.O.M., Coelingh Bennink H.J.T. Ovarian function with a novel combined contraceptive vaginal ring. Hum Reprod. 17:2002;2594-2599.
7. Wynn V. Oral contraceptives and coronary heart disease. J Reprod Med. 36:1991;219-225.
8. Newton J.R. Classification and comparison of oral contraceptives containing new generation progestogens. Human Reprod Update. 1:1995;231-263.
9. Collins D. Selectivity information on desogestrel. Am J Obstet Gynecol. 168:1993;1010-1016.
10. Penttilä I.M., Voutilainen E., Laitinen P., Juutilainen P. Comparison of different analytical and precipitation methods for direct estimation of serum high-density lipoprotein cholesterol. Scand J Clin Lab Invest. 41:1981;353-360.
11. Kostner G.M., Molinari E., Pichler P. Evaluation of a new HDL2/HDL3 quantification method based on precipitation of propylene glycol. Clin Chim Acta. 148:1985;139-147.
12. Godsland I.F., Winkler U., Lidegaard O., Crook D. Occlusive vascular diseases in oral contraceptive users. Epidemiology, pathology and mechanisms. Drugs. 60:2000;721-869.
13. Godsland I.F., Crook D. Pathogenesis of vascular disease in oral contraceptive users. Br J Cardiol. 3:1996;204-208.
14. Åkerlund M., Almström E., Högstedt S., Nabrink M. Oral contraceptive tablets containing 20 and 30 micrograms of ethinyl estradiol with 150 micrograms desogestrel. Their influence on lipids, lipoproteins, sex hormone binding globulin and testosterone. Acta Obstet Gynecol Scand. 73:1994;136-143.
15. Wood D., De Backer G., Faergeman O., Graham I., Mancia G., Pyörälä K., members of the Task Force. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J. 19:1998;1434-1503.
16. Mayes P.A. Lipid transport and storage. Murray R.K., Grunner D.K., Mayes P.A., Rodwell V.W. Harper's biochemistry. 25th ed:2000;268-284 Appleton & Lange, Stamford.
17. Porkka K.V.K., Erkkola R., Taimela S., Raitakari O.T., Dahlen G.H., Viikari J.S.A. Influence of oral contraceptive use on lipoprotein (a) and other coronary heart disease risk factors. Ann Med. 27:1995;193-198.
18. Deckers G.H., Schoonen W.G., Kloosterboer H.J. Influence of the substitution of 11-methylene, delta(15), and/or 18-methyl groups in norethisterone on receptor binding, transactivation assays and biological activities in animals. J Steroid Biochem Mol Biol. 74:2000;83-92.
19. Brien T.G. Human corticosteroid binding globulin. Clin Endocrinol (Oxf). 14:1981;193-212.